Breast Cancer Trials

SWOG 1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

• Women ages 18 and older, diagnosis of breast cancer with positive estrogen (ER)- and/or progesterone-receptor (PR) status, and negative (HER)2 receptor, for whom standard adjuvant endocrine therapy is planned. For additional criteria, call our Clinical Trials office at (910) 715-2200.

ACCRU RU011201I: A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- of Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

• Men or women ages 18 and older, diagnosed with Stage IIIC or IV breast cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

COLET (WO29479): A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer

• Men or women ages 18 and older, diagnosed with metastatic or locally advanced, triple-negative breast cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

• Men or women ages 18 and older, diagnosed with HER2 negative triple-negative invasive breast cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

NSABP B-55 (OlympiA): A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

• Men or women ages 18 and older, diagnosed with non-metastatic breast cancer that is one of the following phenotypes:
  1. Triple negative breast cancer defined as: ER and PgR negative AND HER2 negative (not eligible for anti-HER2 therapy)
  2. ER and/or PgR positive, HER2 negative
  For additional criteria, call our Clinical Trials office at (910) 715-2200.

NSABP B-54I (PENELOPEB): Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy "PENELOPEB"

• Women ages 18 and older, diagnosed with HR positive breast cancer. For additional criteria, call our Clinical Trials office at (910) 715-2200.

AFT-05 (PALLAS): PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

• Men or women ages 18 and older, diagnosed with Stage II or Stage III early invasive breast cancer (ER+ and/or PR+, HER2-). For additional criteria, call our Clinical Trials office at (910) 715-2200.

• Atrial Fibrillation
• Breast Cancer
• Cervical Cancer
• Endometrial Cancer
• Fallopian Tube Cancer
• Colorectal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer
• Venous Thromboembolism - Cancer Related
• Lymphomas
• Kidney Cancer
• Lung Cancer
• Multiple Myeloma
• Ovarian Cancer
• Peritoneal Cancer
• Prostate Cancer
• Solid Tumors